The present disclosure also provides LAG3 binders that bind to LAG3 comprising CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65); CDR2 comprising the amino acid sequence AISESGGRTH (SEQ ID NO: 66); and CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYDY (SEQ ID NO: 67), *e.g.*, comprising the amino acid sequence: EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG RFTISRDNSK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLVTV SS (SEQ ID NO: 64).

In one aspect, there is provided a multispecific binder comprising an immunoglobulin single variable domain (ISVD) that binds PD1 and an ISVD that binds LAG3, wherein the ISVD that binds to PD1 comprises the amino acid sequence:
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYY
ADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 57) or said sequence optionally comprising a D1E mutation;
EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTAIYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 98) or said sequence optionally comprising a E1D mutation;
EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 99) or said sequence optionally comprising a E1D mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS (SEQ ID NO: 103) or said sequence optionally comprising a D1E and/or N73S mutation;
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS(SEQ ID NO: 104) or said sequence optionally comprising a D1E mutation;
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS(SEQ ID NO: 105) or said sequence optionally comprising a D1E mutation;
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 113) or said sequence optionally comprising a D1E mutation;
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 117) or said sequence optionally comprising a D1E mutation; or
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR
DSSKNTVYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 121) or said sequence optionally comprising a D1E mutation.

In another aspect, there is provided a multispecific binder comprising an ISVD that binds PD1 and an ISVD that binds LAG3 wherein

(a) the ISVD that binds to PD1 comprises the amino acid sequence
DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFVAV ITWSGGITYY
ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYWG QGTLVTVSS
(SEQ ID NO: 57);
EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTAIYYCAGDKHQSSWYDYWGQGTLVTVSS
(SEQ ID NO: 98);
EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS
(SEQ ID NO: 99);
DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS
(amino acids 1-119 of SEQ ID NO: 101);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDNSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 103);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 104); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 105); and,

(b) the ISVD that binds to LAG3 comprises the amino acid sequence

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG
RFTISRDNSK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLVTV SS

(SEQ ID NO: 64); or

DVQLVESGGGVVQPGGSLRLSCAASGRTFSDYVMGWFRQAPGKEREFVAAISESGGRTHYADSVKGRFTISRDNSKNT
LYLQMNSLRPEDTALYYCATTLLWWTSEYAPIKANDYDYWGQGTLVTVSS

(amino acids 1-128 of SEQ ID NO: 96).

In another aspect, there is provided a multispecific binder that binds PD1 and LAG3 comprising:

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a human serum albumin (HSA) ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;

- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein the Asp at position 1 is replaced with a Glu);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein the Asp at position 1 is substituted with a Glu);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein the Asp at position 1 is replaced with a Glu);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein the Asp at position 1 is replaced with a Glu);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO:103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO:103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

wherein said residue numbers are Kabat residue numbers.

The PD1 and LAG3 binders may be in a single molecule such as a PD1/LAG3 binder, which is part of the present disclosure, that binds to PD1 and LAG3 that comprises: a PD1 binder comprising: CDR1 comprising the amino acid sequence IHAMG (SEQ ID NO: 3) or GSIASIHAMG (SEQ ID NO: 6); CDR2 comprising the amino acid sequence VITXSGGITYYADSVKG (SEQ ID NO: 4; wherein X is W or V) or VITXSGGITY (SEQ ID NO: 7; wherein X is W or V); and CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5, wherein X is W or F); and a LAG3 binder comprising: CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65); CDR2 comprising the amino acid sequence AISESGGRTH (SEQ ID NO: 66); and CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYDY (SEQ ID NO: 67); and, optionally, a half-life extender.

In an example, the PD1 binder comprises the amino acid sequence:

DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFVAV ITWSGGITYY ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYWG QGTLVTVSS; and (SEQ ID NO: 57); and the LAG3 binder comprises the amino acid sequence:

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG RFTISRDNSK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLVTV SS (SEQ ID NO: 64); and, optionally, a half-life extender. In an example of the disclosure, the PD1/LAG3 binder comprises the moieties, *e.g.*, in the order shown:

- the PD1 binder 102C12 (E1D,L11V,A14P,A74S,K83R,I89L) or 1PD102C12 (E1D, L11V, A14P, W52aV, N73X (*e.g.*, N73P or N73Q or N73S), A74S, K83R, I89L, W100aF);
- a peptide linker such as 9GS, 20GS or 35 GS (*e.g.*, GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 70));
- the LAG3 binder 11B09 or 11B09 (L11V,A14P,R41P,N43K,A62S,A74S,K83R,V89L);
- a peptide linker such as 9GS, 20GS or 35 GS (*e.g.*, GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 70));
- a half-life extender such as ALB11002; and, optionally,

We claim:

1. A multispecific binder comprising an immunoglobulin single variable domain (ISVD) that binds PD1 and an ISVD that binds LAG3, wherein the ISVD that binds to PD1 comprises the amino acid sequence:

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYY ADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 57) or said sequence optionally comprising a D1E mutation;

EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTAIYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 98) or said sequence optionally comprising a E1D mutation;

EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS(SEQ ID NO: 99) or said sequence optionally comprising a E1D mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS (SEQ ID NO: 103) or said sequence optionally comprising a D1E and/or N73S mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS(SEQ ID NO: 104) or said sequence optionally comprising a D1E mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS(SEQ ID NO: 105) or said sequence optionally comprising a D1E mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 113) or said sequence optionally comprising a D1E mutation;

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 117) or said sequence optionally comprising a D1E mutation; or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDSSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS (amino acids 1-119 of SEQ ID NO: 121) or said sequence optionally comprising a D1E mutation.

2. The multispecific binder of claim 1, wherein the ISVD that binds LAG3 comprises the amino acid sequence set forth in SEQ ID NO: 64 or SEQ ID NO: 64 comprising a substitution of the Asp at position 1 with a Glu.

3. The multispecific binder of claim 1, wherein the multispecific binder further includes an ISVD that binds to human serum albumin comprising CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 60 or amino acids 1-5 of SEQ ID NO: 60; CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 61 or amino acids 1-10 of SEQ ID NO: 61; and CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 62.

4. A multispecific binder comprising an ISVD that binds PD1 and an ISVD that binds LAG3 wherein

(a) the ISVD that binds to PD1 comprises the amino acid sequence

DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFVAV ITWSGGITYY ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYWG QGTLVTVSS

(SEQ ID NO: 57);

EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTAIYYCAGDKHQSSWYDYWGQGTLVTVSS

(SEQ ID NO: 98);

EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS

(SEQ ID NO: 99);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGTLVTVSS

(amino acids 1-119 of SEQ ID NO: 101);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDNSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 103);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDQSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 104); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDPSKNT VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGTLVTVSS

(SEQ ID NO: 105); and,

(b) the ISVD that binds to LAG3 comprises the amino acid sequence

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG RFTISRDNSK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLVTV SS

(SEQ ID NO: 64); or

DVQLVESGGGVVQPGGSLRLSCAASGRTFSDYVMGWFRQAPGKEREFVAAISESGGRTHYADSVKGRFTISRDNSKNT LYLQMNSLRPEDTALYYCATTLLWWTSEYAPIKANDYDYWGQGTLVTVSS

(amino acids 1-128 of SEQ ID NO: 96).

5. The multispecific binder of claim 4, wherein the C-terminal extender is an alanine.

6. A multispecific binder that binds PD1 and LAG3 comprising:

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a human serum albumin (HSA) ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and

- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein the Asp at position 1 is replaced with a Glu);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein the Asp at position 1 is substituted with a Glu);

- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein the Asp at position 1 is replaced with a Glu);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein the Asp at position 1 is replaced with a Glu);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO:103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO:103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and

- a C-terminal Alanine

wherein said residue numbers are Kabat residue numbers.

7. The multispecific binder of claim 6, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123 or 124.

8. An injection device or vessel that comprises the multispecific binder of any one of claims 4 to 6, optionally in association with a further therapeutic agent.

9. A composition comprising a multispecific binder of any one of claims 4 to 6 and at least one pharmaceutically acceptable carrier, diluent or excipient.

10. The composition of claim 9, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, or 124.

11. The composition of claim 10, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO:110.

12. A multispecific binder consisting of the amino acid set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, or 124.

13. A composition comprising the multispecific binder of claim 12 and at least one pharmaceutically acceptable carrier, diluent or excipient.

14. A multispecific binder consisting of the amino acid set forth in SEQ ID NO: 110.

15. A composition comprising the multispecific binder of claim 14 and at least one pharmaceutically acceptable carrier, diluent or excipient.

16. A multispecific binder comprising a programmed cell death protein 1 (PD1) binder having the amino acid sequence set forth in SEQ ID NO: 57 and a lymphocyte activation gene 3 (LAG3) binder having the amino acid sequence set forth in SEQ ID NO: 64.

17. The multispecific binder of claim 16, wherein the multispecific binder further comprises a human serum albumin (HSA) binder having the amino acid sequence set forth in SEQ ID NO: 59.

18. A multispecific binder comprising an N-terminal immunoglobulin single variable domain (ISVD) that binds programmed cell death protein 1 (PD1) comprising the amino acid sequence set forth in SEQ ID NO: 57; an ISVD that binds lymphocyte activation gene 3 (LAG3) comprising the amino acid sequence set forth in SEQ ID NO: 64; an ISVD that binds human serum albumin (HSA) comprising the amino acid sequence set forth in SEQ ID NO: 59; and a C-terminal Alanine.

19. A multispecific binder comprising an N-terminal immunoglobulin single variable domain (ISVD) that binds programmed cell death protein 1 (PD1) comprising the amino acid sequence set forth in SEQ ID NO: 57; a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58; an ISVD that binds lymphocyte activation gene 3 (LAG3) comprising the amino acid sequence set forth in SEQ ID NO: 64; a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58; an ISVD that binds human serum albumin (HSA) comprising the amino acid sequence set forth in SEQ ID NO: 59; and a C-terminal Alanine.

20. A composition comprising the multispecific binder of claim 17 and at least one pharmaceutically acceptable carrier, diluent or excipient.

21. A multispecific binder comprising the amino acid set forth in SEQ ID NO: 110.